Xiumei Liang

机构：Tumor Hospital of Guangxi Medical University

发表论文 60 篇 · 总被引 554 次 · h-index 14

代表论文

• Multicenter, retrospective GUIDANCE001 study comparing transarterial chemoembolization with or without tyrosine kinase and immune checkpoint inhibitors as conversion therapy to treat unresectable hepatocellular carcinoma: Survival benefit in intermediate or advanced, but not early, stages (2025 · Hepatology · 被引 27)
• Treatment Duration of Adjuvant Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Patients at High Risk of Recurrence after Resection: A Prospective, Multicentric Cohort Study (2024 · Liver Cancer · 被引 14)
• Prognostic value of aspartate aminotransferase/alanine aminotransferase ratio in hepatocellular carcinoma after hepatectomy (2024 · BJS Open · 被引 12)
• Associations between modifiable risk factors and hepatocellular carcinoma: a trans-ancestry Mendelian randomization study (2024 · BMC Cancer · 被引 11)
• Potentially functional genetic variants in ferroptosis‐related CREB3 and GALNT14 genes predict survival of hepatitis B virus‐related hepatocellular carcinoma (2023 · Cancer Medicine · 被引 9)
• Prognostic value of radiological and pathological complete response following immune-based conversion therapy in patients with unresectable hepatocellular carcinoma (GUIDANCE004) (2025 · JHEP Reports · 被引 7)